Production and use of red blood cells
The present disclosure relates to the production of red blood cells from hematopoietic stem cells, by differentiating such cells in the presence of a protein that induces cell survival and proliferation.
1. A method for increasing the viability of a population of primary mature red blood cells in vitro comprising:
treating the population of primary mature red blood cells in a culture media comprising a TAT-Bcl-2 fusion protein, wherein said treating results in increased viability in the population of primary mature red blood cells when compared to an untreated control.
2. The method of claim 1 , wherein the population of primary mature red blood cells is produced by in vitro differentiation of hematopoietic stem cells.
3. The method of claim 1 , wherein the population of primary mature red blood cells is obtained from peripheral blood of a subject.
4. The method of claim 1 , wherein the population of primary mature red blood cells is an RBC concentrate.
5. The method of claim 1 , wherein the population of primary mature red blood cells is a clinical RBC product.
6. The method of claim 1 , wherein the culture media is a red blood cell storage media.
7. The method of claim 1 , wherein the TAT-Bcl-2 fusion protein is provided in the culture media as a single bolus or provided in the culture media at intervals.
8. The method of claim 1 , wherein the TAT-Bcl-2 fusion protein is provided in the culture media every 24 hours, every 48 hours, every 72 hours, or every 96 hours.
9. The method of claim 1 , wherein the TAT-Bcl-2 fusion protein is provided in the culture media at a concentration of 0.5 μg/ml to 100 μg/ml.
10. The method of claim 1 , wherein the TAT-Bcl-2 fusion protein is provided in the culture media at a concentration of 1 μg/ml, 5 μg/ml, 10 μg/ml, 25 μg/ml, or 50 μg/ml.